Espicom's in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year. Ukraine is the second-largest republic of the former Soviet Union. With a population of almost 50 million, it is also one of the larger countries in Europe as a whole. For this reason, Ukraine represents a potentially major and lucrative pharmaceutical market. In practice, this is not the case. Most domestic manufacturers are very small and focus on the production of older drugs. A number of pharmaceutical manufacturers have managed to obtain GMP certificates, but realistically they can only compete with Western imports in terms of price.

Although an amendment to the Law on Medicines in 2006 provided protection against unfair commercial use of pharmaceutical data submitted in the marketing approval process, serious problems remain with regard to the enforcement of intellectual property rights. Domestic companies tend to produce copies of Western drugs and the judicial system's lack of experience in dealing with IP violations enables this kind of activity to continue. The US government listed Ukraine on its Priority Watch List in 2007.